Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. - Wikidata - awgldk - TriplyDB

Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.

Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.

http://www.wikidata.org/entity/Q36251337

about

The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review Bevacizumab for glioblastoma Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care Two Patients With Brain Tumors Who Received Bevacizumab and Radiotherapy: Optic Neuropathy and Quality-of-Life Issues Multimodal management of muscle-invasive bladder cancer Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Interferon-β inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10.Fool's gold, lost treasures, and the randomized clinical trial.The future of high-grade glioma: Where we are and where are we going.Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma Dose-dense temozolomide: is it still promising?Relief Effect of Bevacizumab on Severe Edema Induced by Re-irradiation in Brain Tumor Patients Efficacy and safety of bevacizumab for the treatment of glioblastoma.Bevacizumab for glioblastoma: current indications, surgical implications, and future directions Bevacizumab for the treatment of glioblastoma.Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.Updates in the management of high-grade glioma.Bevacizumab for glioblastoma-a promising drug or not?Targeted therapy in gliomas.Incorporation of biomarkers in phase II studies of recurrent glioblastoma.Bevacizumab in high-grade gliomas: past, present, and future.Novel chemotherapeutics and other therapies for treating high-grade glioma.Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials.Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma.Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143.Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin.Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature.Trends in Malignant Glioma Monoclonal Antibody Therapy.A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma.

P2860

Q26752321-8D0A9F90-1879-494F-98D2-FD1A13CFDB83 Q26776307-C3BA779A-5B42-4B8E-A452-BAEE05E5683C Q26824777-4513F524-11D6-4269-8E45-7E9FCA7590C3 Q26851160-56E79FB9-06A7-4C07-AC09-120522D857C8 Q26853684-FB3F4094-EC6D-4B4B-AEAD-E54A78E2DD0E Q27011624-C41141CA-C392-412F-8C80-823653C8A413 Q30616602-77A6C155-D0B1-4BCB-B882-519248DA9466 Q34372146-594BFCFD-75B5-466D-9644-CE430820F9D2 Q34669260-9B82E663-2A83-47AC-AE82-4D136D15751B Q35114090-F85CEE27-B041-467A-83F2-FC5551538567 Q35869497-7A3C556F-72D6-486A-916B-B6AABD32AFFB Q35943654-00095BDF-04BF-4215-AD20-321239EBB5BE Q36477223-C66A3942-C318-4FC9-A970-0DF6DE6A4ED6 Q36523864-26B24F7A-D743-4760-B638-4A6C40087E4B Q36822207-BE9E83D2-A2AB-4DB0-8B3D-80170A466E0D Q36929502-935C7212-5874-4550-A6AD-85E918CF50FA Q37592456-454C5E06-D992-4A6A-AAAE-ACFF7B088E5F Q38121772-9B894884-E2B9-40A8-BB8E-70DAEE5C7DCF Q38161401-4326972E-8728-42F1-A496-A8953D484FCA Q38186656-2DC7BDC9-65CD-4142-B4AD-2905D64242B6 Q38298124-F5C33B8A-8360-492A-A066-C2E997BA6C10 Q38386873-1F1B3BAF-07AA-4F7C-BF6C-790829E80955 Q38569802-C451A246-7164-4BA2-8734-E04987D85AE0 Q38867048-23B48642-DCC2-4B3C-9A6A-0BE39BFE9FE3 Q39225820-C93F394C-0E4A-411C-8A0A-D0D0C8DB6824 Q39339970-E0ABA5A6-4DF0-462D-A097-C947904AAFDD Q39799485-F4DE66BA-56DE-49A7-9E77-E8F7BE93CD26 Q39860668-FB01E550-C634-415D-99CE-20E6D1BE85DA Q40979569-BCE42B69-8CF5-456D-995D-188ADA3AB9E3 Q46675575-91423BFF-AAB6-46CB-9D46-0A7EDBBF00DC Q47832964-E291C0C0-64DF-4D30-91DD-4F5647FB6F46 Q48192001-64E57644-F736-4056-A888-D2B04CC4FAE0 Q49066603-788A4920-082D-4DD2-A952-27E8878441CB Q49635346-53E6F163-5012-47CF-9173-2209964B3339 Q54942652-6D5C8AA7-2AF7-408C-AC23-0B8AC536DAEE Q55001435-0EE61E81-2D89-4854-98E4-C4036CC36336

P2860

Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.

http://www.wikidata.org/entity/Q36251337

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Phase II study of single-agent ...... th recurrent malignant glioma.

@ast

Phase II study of single-agent ...... th recurrent malignant glioma.

@en

type

label

Phase II study of single-agent ...... th recurrent malignant glioma.

@ast

Phase II study of single-agent ...... th recurrent malignant glioma.

@en

prefLabel

Phase II study of single-agent ...... th recurrent malignant glioma.

@ast

Phase II study of single-agent ...... th recurrent malignant glioma.

@en

P1433

Q36251337-D6E61708-79DE-4BE0-8BF5-9E67E6F82839

P1476

Q36251337-FC771D56-8B5E-45A4-9D8E-E12C8C3A87EB

P2093

Q36251337-014E4BF1-74D8-4BEC-AF90-E65FEFC36F07

Q36251337-13D0EA95-978F-408F-B4EF-3626E9A8E2C7

Q36251337-2337C81B-9C5C-49D1-8949-D252DB809FFE

Q36251337-2AF1E1D9-A243-4A0B-B177-C29C4C70A6D6

Q36251337-2DEFB498-1B52-402B-9D0C-A0EA0067B9AD

Q36251337-3218A7F5-A9BA-494E-B2AC-1877B08A1B66

Q36251337-32E0C48B-1815-42ED-B916-286535895230

Q36251337-4C032827-9340-4B2A-B21F-01974E55D140

Q36251337-80119B1F-E263-47D7-8BFE-849B57DC30DB

Q36251337-809DE5F2-C13D-4711-9949-37DDC016119F

P2860

Q36251337-05A6520D-38DD-46CF-8912-26F98FBCFBF1

Q36251337-093B9B61-BA34-4DF7-B796-394200B47741

Q36251337-1EAC3216-7BC7-42E2-953E-20CEF7DF724F

Q36251337-2223B663-A635-4AC2-890D-1A22CF196002

Q36251337-2A9FFEAB-62CF-409A-AECF-EA0BC7A7D6DB

Q36251337-42121495-B133-4C09-AAAC-CA9FEBA81740

Q36251337-55F0332B-ABD8-48EC-B984-E308CDEEB9AF

Q36251337-5C8578D3-6955-4B84-AF75-B784104ACBCA

Q36251337-605CAA00-563C-45A7-8DAB-3348095F5FC4

Q36251337-636772AF-ED4F-4F1D-B29E-007798D43F11

P304

Q36251337-EF34806B-A09D-486A-817A-337567F3E1BB

P31

Q36251337-56282818-0F57-4A87-B065-FC3CDCB58D17

P356

Q36251337-6307A879-1C6D-4957-BA13-C150CC479C20

P433

Q36251337-7E7A5015-9821-4114-BE53-5B57AD7C90C1

P478

Q36251337-0A4F2936-CB80-49CD-92A7-6576EE8B9579

P577

Q36251337-EA1D0C73-698B-49A9-83FB-E48FEB8CE17A

P5875

Q36251337-F4893C7B-B2C2-4518-BEDC-9E463ACCF819

P698

Q36251337-DCAE785C-9AEE-4579-A685-31270B6DEFD2

P921

Q36251337-88E02F9D-46B8-4735-B6EE-09B146F322C0

P932

Q36251337-FF34C83E-7CB4-4C40-AAB4-4301AFE51308

P356

P1433

Japanese Journal of Clinical Oncology

P1476

Phase II study of single-agent ...... th recurrent malignant glioma.

@en

P2093

Hiroyuki Kobayashi

http://www.w3.org/2001/XMLSchema#string

Junichi Kuratsu

http://www.w3.org/2001/XMLSchema#string

Kazuhiko Sugiyama

http://www.w3.org/2001/XMLSchema#string

Masao Matsutani

http://www.w3.org/2001/XMLSchema#string

Motoo Nagane

http://www.w3.org/2001/XMLSchema#string

Nobusada Shinoura

http://www.w3.org/2001/XMLSchema#string

Ryo Nishikawa

http://www.w3.org/2001/XMLSchema#string

Shingo Takano

http://www.w3.org/2001/XMLSchema#string

Tomokazu Aoki

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Muragaki

http://www.w3.org/2001/XMLSchema#string

P2860

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

P304

887-895

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JJCO/HYS121

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230586461

http://www.w3.org/2001/XMLSchema#string

P698

22844129

http://www.w3.org/2001/XMLSchema#string

P921

P932

3448378

http://www.w3.org/2001/XMLSchema#string